BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 33510588)

  • 1. Prognostic value of low skeletal muscle mass in hepatocellular carcinoma patients treated with sorafenib or lenvatinib: A meta-analysis.
    Guan J; Yang Q; Chen C; Wang G; Zhu H
    EXCLI J; 2021; 20():1-16. PubMed ID: 33510588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and role of low skeletal muscle mass (LSMM) in hepatocellular carcinoma. A systematic review and meta-analysis.
    March C; Omari J; Thormann M; Pech M; Wienke A; Surov A
    Clin Nutr ESPEN; 2022 Jun; 49():103-113. PubMed ID: 35623801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and Effect of Low Skeletal Muscle Mass among Hepatocellular Carcinoma Patients Undergoing Systemic Therapy: A Systematic Review and Meta-Analysis.
    Kuo MH; Tseng CW; Hsu CS; Chen YC; Kao IT; Wu CY; Shao SC
    Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skeletal muscle mass is associated with toxicity, treatment tolerability, and additional or subsequent therapies in patients with hepatocellular carcinoma receiving sorafenib treatment.
    Sawada K; Saitho Y; Hayashi H; Hasebe T; Nakajima S; Ikuta K; Fujiya M; Okumura T
    JGH Open; 2019 Aug; 3(4):329-337. PubMed ID: 31406927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of lenvatinib
    Jaiswal V; Hameed M; Naz S; Roy P; Deb N; Ukrani J; Krishna Mohan GV; Taha AM; Huang H; Kumar V; Vachhani B; Attia AM; Nath SD; Solimn MA; Mukherjee D
    JGH Open; 2023 Dec; 7(12):832-840. PubMed ID: 38162860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma: A meta-analysis.
    Luo J; Gao B; Lin Z; Fan H; Ma W; Yu D; Yang Q; Tian J; Yang X; Li B
    Front Oncol; 2022; 12():1010726. PubMed ID: 36620586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Low Muscle Mass on Hepatocellular Carcinoma Patients Undergoing Transcatheter Liver-Directed Therapies: Systematic Review & Meta-Analysis.
    Chen YC; Kuo MH; Hsu CS; Kao IT; Wu CY; Tseng CW; Shao SC
    Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the effects of lenvatinib and sorafenib on survival in patients with advanced hepatocellular carcinoma: A systematic review and meta-analysis.
    Hu L; Zheng Y; Lin J; Shi X; Wang A
    Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102061. PubMed ID: 36473632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total skeletal, psoas and rectus abdominis muscle mass as prognostic factors for patients with advanced hepatocellular carcinoma.
    Wu CH; Liang PC; Hsu CH; Chang FT; Shao YY; Ting-Fang Shih T
    J Formos Med Assoc; 2021 Jan; 120(1 Pt 2):559-566. PubMed ID: 32651043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.
    Han Y; Zhi WH; Xu F; Zhang CB; Huang XQ; Luo JF
    World J Gastroenterol; 2021 May; 27(19):2415-2433. PubMed ID: 34040331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of skeletal muscle mass during tyrosine kinase inhibitor (TKI) therapy in cancer patients: a systematic review and meta-analysis.
    Rinninella E; Cintoni M; Raoul P; Ponziani FR; Pompili M; Pozzo C; Strippoli A; Bria E; Tortora G; Gasbarrini A; Mele MC
    Intern Emerg Med; 2021 Aug; 16(5):1341-1356. PubMed ID: 33337518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety comparison between Lenvatinib and Sorafenib in hepatocellular carcinoma treatment: a systematic review and meta-analysis of real-world study.
    Hua X; Yin Z; Liang J; Chen W; Gong H
    Eur J Gastroenterol Hepatol; 2024 Jan; 36(1):120-128. PubMed ID: 37942731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interstitial Brachytherapy for Hepatocellular Carcinoma: Analysis of Prognostic Factors for Overall Survival and Progression-Free Survival and Application of a Risk Stratification Model.
    Thormann M; Heitmann F; Wrobel V; Heinze C; March C; Hass P; Damm R; Surov A; Pech M; Omari J
    Dig Dis; 2023; 41(6):957-966. PubMed ID: 37385234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenvatinib versus sorafenib as first-line therapy of advanced hepatocellular carcinoma: a systematic review and meta-analysis.
    Facciorusso A; Tartaglia N; Villani R; Serviddio G; Ramai D; Mohan BP; Chandan S; Abd El Aziz MA; Evangelista J; Cotsoglou C; Ambrosi A
    Am J Transl Res; 2021; 13(4):2379-2387. PubMed ID: 34017396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis.
    Rimini M; Rimassa L; Ueshima K; Burgio V; Shigeo S; Tada T; Suda G; Yoo C; Cheon J; Pinato DJ; Lonardi S; Scartozzi M; Iavarone M; Di Costanzo GG; Marra F; Soldà C; Tamburini E; Piscaglia F; Masi G; Cabibbo G; Foschi FG; Silletta M; Pressiani T; Nishida N; Iwamoto H; Sakamoto N; Ryoo BY; Chon HJ; Claudia F; Niizeki T; Sho T; Kang B; D'Alessio A; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimur T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Naganuma A; Koizumi Y; Nakamura S; Joko K; Iijima H; Hiasa Y; Pedica F; De Cobelli F; Ratti F; Aldrighetti L; Kudo M; Cascinu S; Casadei-Gardini A
    ESMO Open; 2022 Dec; 7(6):100591. PubMed ID: 36208496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma.
    Nair A; Reece K; Donoghue MB; Yuan WV; Rodriguez L; Keegan P; Pazdur R
    Oncologist; 2021 Mar; 26(3):e484-e491. PubMed ID: 33044793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Role of Low-Skeletal Muscle Mass on Staging Computed Tomography in Metastasized Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Meyer HJ; Strobel A; Wienke A; Surov A
    Clin Colorectal Cancer; 2022 Sep; 21(3):e213-e225. PubMed ID: 35792019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma.
    Kim S; Kim KH; Kim BK; Park JY; Ahn SH; Kim DY; Kim SU
    J Gastroenterol Hepatol; 2021 May; 36(5):1317-1325. PubMed ID: 33217054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Varying impact of lenvatinib or sorafenib therapy on skeletal muscle loss in patients with hepatocellular carcinoma.
    Yamauchi Y; Saeki I; Fujisawa K; Egusa M; Nishiyama N; Fujioka T; Kawamoto D; Sasaki R; Nishimura T; Tanabe N; Hisanaga T; Matsumoto T; Ishikawa T; Yamasaki T; Takami T
    Oncology; 2024 Jan; ():. PubMed ID: 38286117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.